BioCentury | Dec 5, 2005
Company News

Epitan Ltd management update

Epitan Ltd . (ASX:EPT), Melbourne, Australia Business: Dermatology Resigned: Iain Kirkwood as CEO; he will be replaced by Philippe Wolgen, formerly manager of a pharmaceutical business unit at MOG Group Hired: Hank Agersborg as CSO, formerly...
BioCentury | Nov 21, 2005
Company News

EpiTan, Shire Pharmaceuticals Group plc sales and marketing update

...hair in women. EPT expects to launch VaniqaR in the first quarter of next year. EpiTan Ltd....
BioCentury | Oct 31, 2005
Clinical News

EPT1647: Phase I/II started

...formulation is delivered using transdermal delivery technology (TDS) from TransDermal Technologies Inc. (Lake Park, Fla.). EpiTan Ltd....
BioCentury | Oct 10, 2005
Clinical News

Melanotan: Completed Phase II enrollment

...EPT completed enrollment of 45 subjects in the double-blind, placebo-controlled, Australian Phase II EP008 trial. EpiTan Ltd....
BioCentury | Oct 10, 2005
Clinical News

Melanotan: Phase II started

...EPT started a double-blind, placebo-controlled, Australian Phase II trial in 30 patients. EpiTan Ltd. (ASX:EPT), Melbourne, Australia...
BioCentury | Sep 12, 2005
Clinical News

Melanotan: Phase II start

...Australian Phase II trial in 30 patients to evaluate a single subcutaneous dose of EPT1647. EpiTan...
BioCentury | Aug 8, 2005
Company News

Competitive Technologies Inc., EpiTan, Melanotan Corp. deal

...CTT's portfolio to EPT. CTT is eligible for royalties. Competitive Technologies Inc. (CTT), Fairfield, Conn. EpiTan Ltd....
BioCentury | May 23, 2005
Clinical News

Melanotan: Phase I/II data

...Melanotan was well tolerated with a significant increase in melanin density compared to baseline (p<0.001). EpiTan...
BioCentury | May 16, 2005
Finance

Taking the ADR route

...Australia BNY 8/27/04 Phytopharm OTC PHYOY U.K. BNY 8/18/04 Mayne OTC MAYNY Australia BNY 8/12/04 Epitan...
BioCentury | Mar 31, 2005
Financial News

EpiTan to list on AIM

EpiTan (ASX:EPT) plans to list on LSE's AIM and to raise up to L15 million ($28 million). Teather & Greenwood is adviser and broker. The proceeds will be used to fund development of Melanotan , a...
Items per page:
1 - 10 of 20
BioCentury | Dec 5, 2005
Company News

Epitan Ltd management update

Epitan Ltd . (ASX:EPT), Melbourne, Australia Business: Dermatology Resigned: Iain Kirkwood as CEO; he will be replaced by Philippe Wolgen, formerly manager of a pharmaceutical business unit at MOG Group Hired: Hank Agersborg as CSO, formerly...
BioCentury | Nov 21, 2005
Company News

EpiTan, Shire Pharmaceuticals Group plc sales and marketing update

...hair in women. EPT expects to launch VaniqaR in the first quarter of next year. EpiTan Ltd....
BioCentury | Oct 31, 2005
Clinical News

EPT1647: Phase I/II started

...formulation is delivered using transdermal delivery technology (TDS) from TransDermal Technologies Inc. (Lake Park, Fla.). EpiTan Ltd....
BioCentury | Oct 10, 2005
Clinical News

Melanotan: Completed Phase II enrollment

...EPT completed enrollment of 45 subjects in the double-blind, placebo-controlled, Australian Phase II EP008 trial. EpiTan Ltd....
BioCentury | Oct 10, 2005
Clinical News

Melanotan: Phase II started

...EPT started a double-blind, placebo-controlled, Australian Phase II trial in 30 patients. EpiTan Ltd. (ASX:EPT), Melbourne, Australia...
BioCentury | Sep 12, 2005
Clinical News

Melanotan: Phase II start

...Australian Phase II trial in 30 patients to evaluate a single subcutaneous dose of EPT1647. EpiTan...
BioCentury | Aug 8, 2005
Company News

Competitive Technologies Inc., EpiTan, Melanotan Corp. deal

...CTT's portfolio to EPT. CTT is eligible for royalties. Competitive Technologies Inc. (CTT), Fairfield, Conn. EpiTan Ltd....
BioCentury | May 23, 2005
Clinical News

Melanotan: Phase I/II data

...Melanotan was well tolerated with a significant increase in melanin density compared to baseline (p<0.001). EpiTan...
BioCentury | May 16, 2005
Finance

Taking the ADR route

...Australia BNY 8/27/04 Phytopharm OTC PHYOY U.K. BNY 8/18/04 Mayne OTC MAYNY Australia BNY 8/12/04 Epitan...
BioCentury | Mar 31, 2005
Financial News

EpiTan to list on AIM

EpiTan (ASX:EPT) plans to list on LSE's AIM and to raise up to L15 million ($28 million). Teather & Greenwood is adviser and broker. The proceeds will be used to fund development of Melanotan , a...
Items per page:
1 - 10 of 20